Treatment of the Acute Humoral Rejection in Kidney Allografts
Introduction: Acute humoral rejection (AHR) is a severe complication for renal transplantation usually causing a poor graft prognosis. A recent therapeutic approach with plasmapheresis and intravenous immunoglobulins (IVIg) has being proposed. Purpose: To describe the effectiveness of the treatment...
| Autores: | , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2009 |
| País: | Brasil |
| Institución: | Associação Brasileira de Transplante de Órgãos (ABTO) |
| Repositorio: | Brazilian Journal of Transplantation |
| Idioma: | portugués |
| OAI Identifier: | oai:ojs3.emnuvens.com.br:article/259 |
| Acceso en línea: | https://bjt.emnuvens.com.br/revista/article/view/259 |
| Access Level: | acceso abierto |
| Palabra clave: | Transplante de Rim Rejeição de Enxerto Plasmaferese Imunoglobinas Soro Antilinfocitário Muromonab-CD3 Renal Transplantation Graft Rejection Plasmapheresis Intravenous Immunoglobulins Antilynphocyte Serum Renal transplantation, Graft Rejection, Plasmapheresis, Intravenous Immunoglobulins, Antilynphocyte Serum, Muromonab-CD3 |
| Sumario: | Introduction: Acute humoral rejection (AHR) is a severe complication for renal transplantation usually causing a poor graft prognosis. A recent therapeutic approach with plasmapheresis and intravenous immunoglobulins (IVIg) has being proposed. Purpose: To describe the effectiveness of the treatment of AHR. Patients and methods: From January 2002 to April 2008 fifteen patients were diagnosed as having AHR, and they were treated with plasmapheresis and IVIg or ATG/OKT3 in our institution. Results: Reversal of AHR was attained in twelve (80%) patients. One-year patient and graft survivals were 100% and 73%, respectively. One successfully treated patient had the immunosuppressive regimen discontinued due the presence of sepsis, and the graft was subsequently lost. Conclusion: We concluded that this is an efficient therapeutic, allowing the survival of the majority of grafts. |
|---|